Moreover, a case series of six patients with ototoxic manifestations after receiving ICIs (all of whom received a PD-1 inhibitor as a part of their regimen) showed that most of those encountering ototoxicity had other organ involvement, including uveitis, dermatitis, arthritis, pancreatitis, thyroiditis, and even hypophysitis. Here, PDCD1 is linked to uveitis.